Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · COHANCE

COHANCE

HealthcarePharmaceuticals & Biotechnology₹17462 cr market cap
₹459.45 ▲ +0.67% today As of 19 Nov 2026
52-week low ₹279.9052-week high ₹689.90

-33.8% from the 52-week high · +63.1% above the low

Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.

The short version. COHANCE reported revenue of ₹477 crore for Sep 2026, down 14.2% from a year earlier. Net profit was ₹15 crore (down 79.7% year on year). Return on equity was 4.6% in Mar 2026. Promoter holding was 57.48% in Sep 2026, up 7.38 points over 8 quarters.

1 · The price

How has the stock traded?

COHANCE trades 33.8% below its 52-week high and 63.1% above its 52-week low.

Change over period: —

1M-0.3%
3M+2.1%
6M+8.6%
1Y-23.5%

2 · The business

Is it growing?

Sales, year on year-14.2%

Sep 2026 revenue of ₹477 cr.

Profit, year on year-79.7%

Sep 2026 net profit of ₹15 cr.

Net margin3.2%

10.1 pts lower than a year earlier.

3-year growth-24.2% profit

Revenue compounded at 18.4% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue477422619545556549402307
Net profit15-24203774494283
Net margin %3.2-5.73.26.713.38.910.427.0
EPS (₹)0.4-0.630.510.961.941.281.653.26

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue226911981051134013201010834
Net profit179268300411454362317
Net margin %7.922.428.630.734.435.938.0
EPS (₹)4.6810.5211.816.1617.8314.2312.45

3 · The quality

How well does it turn capital into profit?

Return on equity was 4.6% in Mar 2026; debt to equity is 0.04.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %4.615.814.623.7
Return on capital %4.813.419.231.3
EBITDA margin %18.734.542.044.2
Net margin %7.821.327.029.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR18.4%17.6%
Profit CAGR-24.2%-13.1%
Debt to equity0.04
Interest cover6.6x
Current ratio2.78

4 · The owners

Who holds it, and are they adding?

Promoter holding57.48%

Up 7.38 pts over 8 quarters.

Foreign institutions7.71%

Down 3.13 pts over 8 quarters.

Domestic institutions18.86%

Up 2.18 pts over 8 quarters.

Mutual fund schemes106

+19 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter50.150.166.4157.4957.4957.4957.4957.48+7.38
FII10.8411.057.236.516.025.596.57.71-3.13
DII16.6816.611.420.8221.5721.7920.0918.86+2.18
Public22.3722.2314.9515.1714.9215.1215.9215.95-6.42

Mutual fund holdings · Oct 2026

106 schemes hold this stock

87 the month before.

  • DSP Healthcare Fund3.82% of NAV
  • ICICI Prudential Healthcare Fund3.67% of NAV
  • ITI Pharma and Healthcare Fund3.13% of NAV
  • LIC MF HEALTHCARE FUND3.04% of NAV
  • LIC MF SMALL CAP FUND3.01% of NAV
  • UTI - Healthcare Fund2.79% of NAV
  • LIC MF FLEXI CAP FUND2.63% of NAV
  • LIC MF ELSS TAX SAVER FUND1.96% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for COHANCE are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about COHANCE

What is the COHANCE share price?

COHANCE (COHANCE) last closed at ₹459.45, up 0.67% on the day. Its 52-week range is ₹279.90 to ₹689.90.

What is the market cap of COHANCE?

COHANCE has a market capitalisation of about ₹17,462 crore.

How are COHANCE's latest results?

COHANCE reported revenue of ₹477 crore for Sep 2026, down 14.2% from a year earlier. Net profit was ₹15 crore (down 79.7% year on year). Return on equity was 4.6% in Mar 2026. Promoter holding was 57.48% in Sep 2026, up 7.38 points over 8 quarters.

Who owns COHANCE?

As of Sep 2026, shareholding was: Promoter 57.48%, FII 7.71%, DII 18.86%, Public 15.95%.

How many mutual funds hold COHANCE?

106 mutual fund schemes held COHANCE in October 2026. That compares with 87 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 09 Sep 2022 · Interim Dividend - Rs. 1
  • 09 Sep 2022 · Special Dividend - Rs. 5
  • 13 May 2022 · Interim Dividend - Rs. 1
  • 13 May 2022 · Special Dividend - Rs. 1
  • 15 Feb 2022 · Special Dividend - Rs. 2
  • 15 Feb 2022 · Interim Dividend - Rs. 1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.